Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,240.0
5.5 (0.17%)

 

  • STI Straits Times Index
    3,240.0
    5.5 (0.17%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    31.3 (0.11%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,827.2
    31.7 (0.13%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,244.1
    -5.1 (-0.08%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,203.2
    4.2 (0.06%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 872.5M
  • Value: 729.0M
  • Rise: 113
  • Fall: 130
  • Unch: 575

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.104-0.001
ThaiBev0.795+0.005
Rex Intl0.181+0.007
Spackman0.018+0.002
Golden Agri-Res0.225-
Genting Sing0.910-0.005
Joyas Intl0.003-
OEL0.023-0.001
YZJ Shipbldg SGD1.040-0.020
AusGroup^0.042+0.003

World Indices

World Indices
Name Last Change
Nasdaq 9,314.9 -87.6
HSI 27,940.5 +31.3
HSCEI 10,969.3 +17.0
Jakarta 6,244.1 -5.1
Nikkei 225 23,827.2 +31.7
SSE Comp 2,976.5
Shanghai A 3,118.9
Shanghai B 248.6
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ACTINIUM PHARMACEUTICALS INC ACTINIUM PHARMACEUTICALS INC
Updated on 24 Jan 2020 (End of trading day)
Last (USD): 0.251 Change: - High: 0.260 Remarks: -
Change (%): +0.04 Low: 0.250
Open 0.250 Yesterday's Close 0.2509
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,313,088 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.29560 Trailing EPS (USD) e -0.29514 NAV (USD) b 0.1242
PE a - Trailing PE f - Price / NAV b 2.0209
Dividend (USD) d - Cash In Hand (USD) g 0.1795 Issued & Paid-up Shares c 164,701,000
Dividend Yield (%) d - Price / Cash In Hand g 1.398 Treasury Shares h -
Beta - 75 Daysi 0.971 R-Squared - 75 Days(%)i 4.21 Market Cap (M) 20.085
Beta - 500 Daysi 0.874 R-Squared - 500 Days (%)i 2.08 Enterprise Value (M) 6.975
Piotroski F Score 0 Exchange Code ATNM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 105.21 Free Float (%) 95.7
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 13 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ACTINIUM PHARMACEUTICALS INC NYSE American 20.085 - - 2.0209 -
Industry Biotechnology NYSE American 106.544 - - 4.0488 -
Local Peer NANOVIRICIDES INC NYSE American 532.958 - - 58.3967 -
Local Peer PFENEX INC NYSE American 262.113 - - 4.6945 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 223.846 - - -293.6170 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 155.786 - - 1.3298 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 135.199 - - 3.9816 -
Local Peer CEL-SCI CORP NYSE American 130.331 - - 25.3864 -
Local Peer 22ND CENTURY GROUP INC NYSE American 108.926 - - 1.9695 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 106.671 2.982 2.887 1.1097 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 70.856 - - 690.6250 -
Local Peer ISORAY INC NYSE American 46.005 - - 6.6155 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 26.296 - - 1.4502 -
Local Peer IBIO INC NYSE American 25.897 - - -13.4135 -
Other Local Peers ORAGENICS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), AIM IMMUNOTECH INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American)
Global Peer AMGEN INC NASDAQ 134,041.969 15.969 16.616 12.2671 2.480
Global Peer CSL ASX 141,021.137 52.562 52.563 18.8452 0.854
Global Peer GILEAD SCIENCES INC NASDAQ 79,894.223 14.646 29.667 3.8776 3.659
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 58,902.779 28.097 27.476 11.2123 -
Global Peer BIOGEN INC NASDAQ 50,188.138 11.327 9.302 3.5859 -
Global Peer ILLUMINA INC NASDAQ 46,978.260 56.874 48.282 10.5831 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,910.353 15.509 17.680 3.6090 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,376.752 86.636 25.562 5.7660 0.692
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,295.304 300.197 15.844 2.2470 -
Other Global Peers SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), NEUROCRINE BIOSCIENCES INC (NASDAQ), 10X GENOMICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), 3SBIO (HKEx), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), EPIZYME INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), VIELA BIO INC (NASDAQ), INSMED INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), ALPHAMAB-B (HKEx), ALECTOR INC (NASDAQ), HAOHAI BIOTEC (HKEx), CORTEXYME INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), POLYNOVO LIMITED (ASX), NGM BIOPHARMACEUTICALS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), ROCKET PHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), ENANTA PHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), CKLIFE SCIENCES (HKEx), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), DERMIRA INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), XBIOTECH INC (NASDAQ), INTREXON CORP (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), OMEROS CORP (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), KADMON HLDGS INC (NYSE), RETROPHIN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), NANTKWEST INC (NASDAQ), AVROBIO INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ARDELYX INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MACROGENICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), SINOMAB BIO-B (HKEx), PRECISION BIOSCIENCES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), BELLUS HEALTH INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), ESSEX BIO-TECH (HKEx), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CABALETTA BIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CUE BIOPHARMA INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), LEE'S PHARM (HKEx), SYROS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), MEDICINOVA INC (NASDAQ), GERON CORP (NASDAQ), NEXT SCIENCE LTD (ASX), KAMADA (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), TELIX PHARMACEUTIC (ASX), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), BBI LIFE SCI (HKEx), VBI VACCINES INC CDA (NASDAQ), AFFIMED N V (NASDAQ), IMV INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ATHERSYS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), SYNDAX PHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), XOMA CORP (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VERASTEM INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), SAVARA INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CYMABAY THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ADURO BIOTECH INC (NASDAQ), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), ENZO BIOCHEM INC (NYSE), PARATEK PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), COHBAR INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), OTONOMY INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), IMUGENE LIMITED (ASX), CHAMPIONS ONCOLOGY INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), SYNLOGIC INC (NASDAQ), ORGENESIS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), TREVENA INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), MICROBOT MEDICAL INC (NASDAQ), IMMUTEP LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), VACCINEX INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SOLIGENIX INC (NASDAQ), ORTHOCELL LIMITED (ASX), ALPINE IMMUNE SCIENCES INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CT ENTERPRISE (HKEx), CURIS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), ALIMERA SCIENCES INC (NASDAQ), OCUGEN INC (NASDAQ), BIOCARDIA INC (NASDAQ), BIOSINO BIO-TEC (HKEx), SEELOS THERAPEUTICS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOTRON (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), BIONANO GENOMICS INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), KAZIA THERAPEUTICS LIMITED (ASX), APTEVO THERAPEUTICS INC (NASDAQ), ANTEOTECH LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), AZURRX BIOPHARMA INC (NASDAQ), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), REGENT PACIFIC (HKEx), TALI DIGITAL LIMITED (ASX), AETERNA ZENTARIS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), VAXART INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), MIRAGEN THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), BIO-PATH HOLDINGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PRECIPIO INC (NASDAQ), IMMURON LIMITED (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), BIOCEPT INC (NASDAQ), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), TOCAGEN INC (NASDAQ), TROVAGENE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), REGENEUS LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), SENESTECH INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ADALTA LTD (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), PLUS THERAPEUTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), OPGEN INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), QT Vascular (SGX), LIVING CELL TECHNOLOGIES (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), BIOXYNE LIMITED (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), MEDIBIO LIMITED (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TBG DIAGNOSTICS LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.023
-8.39 %
10 Days -+0.001
+0.40 %
20 Days -+0.032
+14.61 %
Medium Term Return 3 Months --0.102
-28.90 %
6 Months -+0.001
+0.40 %
1 Year --0.301
-54.53 %
Long Term Return 2 Years --0.499
-66.53 %
3 Years --0.809
-76.32 %
5 Years --5.139
-95.34 %
Annualised Return Annualised --
-45.85 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.190 - 0.709 Change From 1 Year Low +0.061 % Change From 1 Year Low (%) +32.11
Change From 1 Year High -0.458 % Change From 1 Year High (%) -64.57
2 Years Range 0.190 - 0.865 Change From 2 Years Low +0.061 % Change From 2 Years Low (%) +32.11
Change From 2 Years High -0.614 % Change From 2 Years High (%) -70.99
5 Years Range 0.190 - 5.505 Change From 5 Years Low +0.061 % Change From 5 Years Low (%) +32.11
Change From 5 Years High -5.254 % Change From 5 Years High (%) -95.44
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
24 Jan 2020 0.250 0.260 0.250 0.251 1,313,088 -
23 Jan 2020 0.250 0.269 0.250 0.251 1,688,405 -
22 Jan 2020 0.260 0.264 0.250 0.252 2,570,034 -
21 Jan 2020 0.270 0.278 0.260 0.264 2,476,982 -
17 Jan 2020 0.278 0.282 0.266 0.274 3,215,881 -
16 Jan 2020 0.260 0.290 0.250 0.280 4,003,838 -
15 Jan 2020 0.282 0.282 0.255 0.255 5,045,457 -
14 Jan 2020 0.300 0.300 0.270 0.276 9,102,506 -
13 Jan 2020 0.270 0.292 0.265 0.274 20,118,690 -
10 Jan 2020 0.253 0.260 0.230 0.250 1,819,467 -
09 Jan 2020 0.240 0.260 0.238 0.252 2,845,936 -
08 Jan 2020 0.240 0.240 0.230 0.238 1,509,641 -
07 Jan 2020 0.240 0.250 0.237 0.243 2,388,150 -
06 Jan 2020 0.240 0.248 0.229 0.234 1,796,860 -
03 Jan 2020 0.240 0.247 0.230 0.240 2,523,226 -
02 Jan 2020 0.227 0.239 0.220 0.238 3,159,341 -
31 Dec 2019 0.226 0.230 0.212 0.218 1,515,538 -
30 Dec 2019 0.229 0.229 0.218 0.227 1,625,310 -
27 Dec 2019 0.231 0.236 0.219 0.219 1,260,095 -
26 Dec 2019 0.220 0.237 0.220 0.231 3,005,822 -
24 Dec 2019 0.203 0.220 0.203 0.219 1,952,846 -
23 Dec 2019 0.200 0.204 0.200 0.203 1,825,774 -
Summary
Current 2 Weeks
(10 Jan 2020 to 24 Jan 2020)
0.253 0.300 0.230 0.251 51,354,348 -
Previous 2 Weeks
(26 Dec 2019 to 09 Jan 2020)
0.220 0.300 0.220 0.252 21,629,919 -
4 Weeks from
(26 Nov 2019 to 24 Dec 2019)
0.210 0.300 0.207 0.219 62,961,786 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.